Spero Therapeutics CEO and leadership

CEO of Spero Therapeutics, a public, clinical stage company developing a pipeline of therapeutics treating large unmet needs in infectious disease. Co-founder of nine biotech startups developing novel platforms and therapies, including Spero Therapeutics (Nasdaq:SPRO), Synlogic (Nasdaq: SYBX), and Arteaus Therapeutics (Acquired by Eli Lilly, Emgality FDA approved by Eli Lilly). Advisor at Atlas Venture, an early stage life sciences and technology venture capital firm. Some more on my perspective at http://lifescivc.com/2014/04/building-great-startup-teams-in-biotech-a-three-hour-tour, http://lifescivc.com/2014/07/growing-beyond-the-startup-phase-lessons-learned, and at https://timmermanreport.com/2018/08/zigging-when-others-zag-speros-ankit-mahadevia-on-the-antibiotic-opportunity.

Cristina Larkin is the Chief Commercial Officer at Spero Therapeutics in Cambridge, MA. Ms. Larkin has over 22 years of experience developing strategic commercial insights for biopharmaceutical companies and their infectious disease products such as Avycaz, Dalvance, Teflaro, Levaquin and Floxin.Prior to joining Spero, she served as Assistant Vice President for Actavis, formerly Forest Laboratories. During that time, Ms. Larkin led the commercial hospital antibiotic franchise team and was responsible for the US launch and execution strategy for several antibiotics. Additionally, she was a member of the business assessments and business development team and played an integral role in the out-licensing of ceftaroline to AstraZeneca, the acquisition of Durata and more. Ms. Larkin received a bachelor’s degree from Florida State University.

Tim Keutzer is the Chief Development Officer at Spero Therapeutics. Tim has over 20 years experience in the pharmaceutical industry, spanning multiple functional and therapeutic areas. Prior to joining Spero, he was Vice President of Program and Portfolio Management at Cubist Pharmaceuticals. While there, he was the program leader for ceftolozane/tazobactam, which progressed rapidly from Phase 1 to Phase 3, and was approved in the US in December of 2014. Prior to that role, he also lead several of Cubist’s in-licensed development programs, and also lead the commercial supply chain for Cubicin.

Dr. David Melnick is the Chief Medical Officer at Spero Therapeutics in Cambridge, MA. Dr. Melnick has 18 years of experience in anti-infective drug development. Prior to joining Spero Therapeutics, Dr. Melnick served as Vice President of Clinical Development for Anti-Infectives at Allergan since 2015. In that capacity, he oversaw the development and regulatory approval of Teflaro®, Avycaz®, and Dalvance® in the United States.

Global-minded and strategic senior executive/board member with extensive experience in publicly and privately held high growth-oriented health care companies, as well as innovative public health non-profits. Skilled at addressing M&A, Litigation, and Corporate Governance issues in complex environments. Broad experience building and leading well-respected legal, compliance, risk management, HR, government and public affairs functions. Demonstrated abilities protecting company assets, minimizing risks and enhancing growth by developing and managing the delivery of high quality, cost-effective services. A trusted member of and advisor to Boards and senior leadership teams.

CEO of Spero Therapeutics, a public, clinical stage company developing a pipeline of therapeutics treating large unmet needs in infectious disease. Co-founder of nine biotech startups developing novel platforms and therapies, including Spero Therapeutics (Nasdaq:SPRO), Synlogic (Nasdaq: SYBX), and Arteaus Therapeutics (Acquired by Eli Lilly, Emgality FDA approved by Eli Lilly). Advisor at Atlas Venture, an early stage life sciences and technology venture capital firm. Some more on my perspective at http://lifescivc.com/2014/04/building-great-startup-teams-in-biotech-a-three-hour-tour, http://lifescivc.com/2014/07/growing-beyond-the-startup-phase-lessons-learned, and at https://timmermanreport.com/2018/08/zigging-when-others-zag-speros-ankit-mahadevia-on-the-antibiotic-opportunity.

CEO of Spero Therapeutics, a public, clinical stage company developing a pipeline of therapeutics treating large unmet needs in infectious disease. Co-founder of nine biotech startups developing novel platforms and therapies, including Spero Therapeutics (Nasdaq:SPRO), Synlogic (Nasdaq: SYBX), and Arteaus Therapeutics (Acquired by Eli Lilly, Emgality FDA approved by Eli Lilly). Advisor at Atlas Venture, an early stage life sciences and technology venture capital firm. Some more on my perspective at http://lifescivc.com/2014/04/building-great-startup-teams-in-biotech-a-three-hour-tour, http://lifescivc.com/2014/07/growing-beyond-the-startup-phase-lessons-learned, and at https://timmermanreport.com/2018/08/zigging-when-others-zag-speros-ankit-mahadevia-on-the-antibiotic-opportunity.

Tom Parr, PhD, has more than 26 years drug discovery experience across both large pharmaceutical and small biotechnology companies. Prior to joining Spero, Dr. Parr was the Chief Scientific Officer at Fedora Pharmaceuticals where the company moved novel diazabicyclooctane beta-lacramase inhibitors toward development partnerships. Prior to Fedora he was the Chief Scientific Officer at Targanta Therapeutics, now part of The Medicines Company. While at Targanta, Dr. Parr was instrumental in progressing the lipoglycopeptide, oritavancin through Phase 3 trials to registration with the FDA. Dr. Parr has worked on a broad range of marketed antibiotics including beta-lactams (cefaclor, loracarbef, cefuroxime axetil, cephalexin, moxalactam, ceftazidime, cefazolin, RWJ-333441); glycopeptides (vancomycin and oritavancin); lipodepsipeptides (daptomycin); aminoglycosides (tobramycin); quinolones (cinoxacin); macrolides (dirythromycin); antimicrobial peptides (iseganins); and a variety of additional developmental candidates. Dr. Parr earned his PhD from the University of Calgary and conducted a postdoctoral fellowship at the University of British Columbia. He was an Assistant Professor in the Department of Microbiology and Biochemistry at the University of Ottawa before beginning his drug discovery and development career.